Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 186,400 shares, a drop of 41.7% from the March 15th total of 319,700 shares. Based on an average daily volume of 274,600 shares, the […]
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price target decreased by Benchmark from $9.00 to $4.00 in a research report released on Tuesday morning, Benzinga reports. Benchmark currently has a speculative buy rating on the stock. A number of other analysts have also recently issued reports on PCSA. Oppenheimer cut their price objective on […]
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price objective reduced by Oppenheimer from $5.00 to $3.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an outperform rating on the stock. Oppenheimer also issued estimates for Processa Pharmaceuticals’ Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at […]
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) – Investment analysts at Oppenheimer decreased their Q1 2023 earnings per share (EPS) estimates for shares of Processa Pharmaceuticals in a research report issued on Monday, April 3rd. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings of ($0.28) per share for the quarter, down […]
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) is set to announce its earnings results after the market closes on Thursday, March 30th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Processa Pharmaceuticals Stock Performance Processa Pharmaceuticals stock opened at $0.48 on Friday. The firm has a market cap of $8.07 […]